SureTrader Nadex Advertisement PGUS
Home > Boards > US Listed > Medical - Healthcare >

Conatus Pharmaceuticals Inc. (CNAT)

CNAT RSS Feed
Add CNAT Price Alert      Hide Sticky   Hide Intro
Moderator: Inoviorulez
Search This Board: 
Last Post: 3/22/2017 2:45:36 PM - Followers: 91 - Board type: Free - Posts Today: 0
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CNAT
Current Price
Volume:
Bid Ask Day's Range
SureTrader
CNAT News: Current Report Filing (8-k) 03/21/2017 04:06:49 PM
CNAT News: Annual Report (10-k) 03/16/2017 04:09:08 PM
CNAT News: Current Report Filing (8-k) 03/15/2017 04:07:43 PM
CNAT News: Conatus Pharmaceuticals Reports 2016 Financial Results and Program Updates 03/15/2017 04:05:00 PM
CNAT News: Conatus Pharmaceuticals to Report Fourth Quarter and Full Year 2016 Financial Results 03/08/2017 04:05:00 PM
PostSubject
#1100  Sticky Note New Research article on Conatus Pharmaceuticals (CNAT) Inoviorulez 01/23/17 04:11:37 PM
#1260   If everything goes according to plan they will staccani 03/22/17 02:45:36 PM
#1259   They don't really have a need for a biotech2010 03/22/17 12:09:06 PM
#1258   So it appears, no change in management. Not realfast95 03/22/17 09:31:55 AM
#1257   Encore LF trial is not necessarily tarGeting terminal staccani 03/18/17 11:55:08 AM
#1256   Perhaps CNAT should open an office in Mexico, realfast95 03/18/17 11:21:28 AM
#1255   Realfast do not confuse drug safety with drug staccani 03/18/17 11:03:25 AM
#1254   So getting back to my questions regarding safety. realfast95 03/18/17 10:19:20 AM
#1253   GALT vs CNAT positioning in Nash Cirrhosis staccani 03/18/17 07:06:11 AM
#1252   GILD vs CNAT positioning in Nash Cirrhosis (attached staccani 03/18/17 02:52:09 AM
#1251   GILD vs CNAT poistioning in Nasc Cirrhosis. staccani 03/18/17 02:51:56 AM
#1250   And like an idiot, I'll probably sell at chainma1l 03/17/17 02:23:24 PM
#1249   Those are very interesting numbers and even if biotech2010 03/17/17 02:00:33 PM
#1248   Market size and market cap staccani 03/17/17 12:39:53 PM
#1247   3/17/2017 HC Wainwright Reiterated Rating Buy $18.00 realfast95 03/17/17 08:46:24 AM
#1246   Another possible treatment is for patients undergoing chemo lorema 03/16/17 05:24:24 PM
#1245   More than 38,000 patients died due to chronic lorema 03/16/17 05:20:09 PM
#1244   Emricasan was initially discovered and developed by researchers lorema 03/16/17 05:04:26 PM
#1243   Another source puts NASH Cirrhosis prevalence in US staccani 03/16/17 05:01:43 PM
#1242   NASH prevalence in US: staccani 03/16/17 04:48:04 PM
#1241   30% of the commercial profit! lorema 03/16/17 04:35:21 PM
#1240   From the just published 10K: staccani 03/16/17 04:30:03 PM
#1239   https://biz.yahoo.com/e/170316/cnat10-k.html 10K Form Theo 03/16/17 04:21:26 PM
#1238   I thought they said all four trials will lorema 03/16/17 04:11:53 PM
#1237   In a couple of points in the Q&A staccani 03/16/17 12:34:24 PM
#1236   Stifel Nicolaus, a major research house, upped their biotech2010 03/16/17 11:10:47 AM
#1235   Today, Aegis reiterated its Buy rating on Conatus realfast95 03/16/17 11:07:45 AM
#1234   Great summary Staccani! Hopefully this stays low lorema 03/16/17 09:00:49 AM
#1233   There are basically 4 parallel and distinct paths staccani 03/16/17 08:17:30 AM
#1232   In 2012, Congress passed the Food and Drug lorema 03/16/17 07:29:14 AM
#1231   They did not say what kind of drugs lorema 03/16/17 07:25:25 AM
#1230   The reason for my question about the Phase realfast95 03/16/17 06:19:34 AM
#1229   Key points in the PR/CC: staccani 03/16/17 02:15:53 AM
#1228   I understood his non-answers. But I stand by realfast95 03/15/17 09:57:32 PM
#1227   I got a completely different read of Dr biotech2010 03/15/17 08:31:01 PM
#1226   The CEO was quite the card. realfast95 03/15/17 07:05:51 PM
#1225   No, they have to use patients that meet biotech2010 03/15/17 05:24:47 PM
#1224   Question on these studies. On a safety study, realfast95 03/15/17 04:55:17 PM
#1223   finance.yahoo.com/news/conatus-pharmaceuticals-reports-2016-financial-20050 Theo 03/15/17 04:18:24 PM
#1222   In addition, Novartis will reimburse 50% of Conatus’ lorema 03/15/17 04:11:01 PM
#1221   Nice pre ER RUN UP bleu22 03/15/17 03:17:20 PM
#1220   3/15/2017 FBR & Co Reiterated Rating Outperform $16.00 realfast95 03/15/17 03:03:02 PM
#1219   https://clinicaltrials.gov/ct2/show/NCT03053063 First impressions: it is a lo staccani 03/13/17 03:03:11 PM
#1218   GILD has just started a ph3 NASH Cirrhosis staccani 03/13/17 02:15:58 PM
#1217   There is certainly some truth to your post fishhunter 03/12/17 09:33:15 PM
#1216   Why did JAZZ Pharmaceuticals trade at $1 per Inoviorulez 03/12/17 10:48:27 AM
#1215   I agree that with successful ph2b trials in staccani 03/08/17 08:19:39 PM
#1214   I agree with you staccani. For me it Inoviorulez 03/08/17 05:10:17 PM
#1213   Me too I'm gonna keep adding until the Inoviorulez 03/08/17 05:07:38 PM
#1212   The ride is going to be bumpy and staccani 03/08/17 02:11:16 PM
#1211   I'm glad I grabbed some more on the dip bleu22 03/08/17 12:21:54 PM
PostSubject